Phenobarbital in the treatment of alcohol withdrawal syndrome

doi:10.3868/j.issn.2096-0689.2022.04.002

Journal of Translational Neuroscience ›› 2022, Vol. 7 ›› Issue (4) :7 -11. DOI: 10.3868/j.issn.2096-0689.2022.04.002

Tiankai Jiang, Lan Jiang, Yinhang Li, Yuhang Liang, Tiantian Jiang, Hongyan Liu^*

Author information +

History +

PDF (5299KB)

Abstract

Alcohol withdrawal syndrome (AWS) is a serious disorder affecting alcohol-dependent patients who abruptly stop or reduce their drinking. Mild or moderate AWS usually appears within 6 to 24 h after the last drink, and symptoms may include increased blood pressure and rapid pulse, tremors, high fever, irritability, anxiety, headache, nausea, and vomiting. These symptoms may progress to a more severe AWS characterized by delirium tremens, seizures, coma, cardiac arrest, and death. This article will analyze the phenobarbital (PB) treatment of AWS and make a brief review.

Keywords

alcohol withdrawal syndrome (AWS) / benzodiazepine (BDZ) / phenobarbital (PB)

Cite this article

Download citation ▾

Tiankai Jiang, Lan Jiang, Yinhang Li, Yuhang Liang, Tiantian Jiang, Hongyan Liu. Phenobarbital in the treatment of alcohol withdrawal syndrome. Journal of Translational Neuroscience, 2022, 7(4): 7-11 DOI:10.3868/j.issn.2096-0689.2022.04.002